Your session is about to expire
← Back to Search
Other
Drug Interaction Study of Sonrotoclax
Phase 1
Waitlist Available
Research Sponsored by BeiGene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Healthy males or healthy females of non-childbearing potential
Be between 18 and 65 years old
Must not have
Evidence of renal impairment at screening
Any contraindication to the use of phenytoin (Part A) or itraconazole (Part B)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from time of providing written informed consent until up to 30 days after the final dose of study treatment for each part of the study; approximately 8 weeks for part a and approximately 7 weeks for part b
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to study how the metabolism of a drug called sonrotoclax is affected by other drugs that either increase or decrease the activity of a specific enzyme in the body. The study will be
Who is the study for?
This trial is for healthy volunteers who want to help study the effects of certain drugs on sonrotoclax, a medication being tested. Participants must not have any health conditions that could interfere with the drug's activity or their safety during the trial.
What is being tested?
The study is looking at how sonrotoclax behaves in the body when taken with either phenytoin (Part A) or itraconazole (Part B). These drugs are known to affect how other drugs are broken down by the liver.
What are the potential side effects?
Possible side effects may include reactions related to liver enzyme changes due to phenytoin and itraconazole, which can alter how sonrotoclax is processed in the body. Specific side effects will be monitored throughout the study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a healthy male or a female who cannot become pregnant.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My kidneys are not working properly.
Select...
I cannot take phenytoin or itraconazole due to health reasons.
Select...
I have been treated with sonrotoclax before.
Select...
I am a current smoker or have smoked in the past year.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from time of providing written informed consent until up to 30 days after the final dose of study treatment for each part of the study; approximately 8 weeks for part a and approximately 7 weeks for part b
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from time of providing written informed consent until up to 30 days after the final dose of study treatment for each part of the study; approximately 8 weeks for part a and approximately 7 weeks for part b
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Parts A and B: Number of Participants with Adverse Events (AEs)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Part B: Itraconazole + SonrotoclaxExperimental Treatment2 Interventions
Part B is designed to determine the effect of multiple doses of itraconazole on sonrotoclax in healthy participants.
Group II: Part A: Phenytoin + SonrotoclaxExperimental Treatment2 Interventions
Part A is designed to determine the effect of multiple doses of phenytoin on sonrotoclax in healthy participants.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Phenytoin
2023
Completed Phase 4
~960
Itraconazole
2017
Completed Phase 2
~830
sonrotoclax
2024
Completed Phase 1
~30
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
BeiGeneLead Sponsor
200 Previous Clinical Trials
31,615 Total Patients Enrolled
1 Trials studying Not Determined
92 Patients Enrolled for Not Determined
Quotient SciencesIndustry Sponsor
50 Previous Clinical Trials
1,544 Total Patients Enrolled
Study DirectorStudy DirectorBeiGene
1,290 Previous Clinical Trials
500,688 Total Patients Enrolled